Oner Ayse, Kahraman Nisa, Ozdamar Saim, Balcioglu Esra
Department of Ophthalmology, Faculty of Medicine, Erciyes University, Kayseri 38039, Turkey.
Department of Histology and Embryology, Faculty of Medicine, Erciyes University, Kayseri 38039, Turkey.
Int J Ophthalmol. 2018 Apr 18;11(4):575-579. doi: 10.18240/ijo.2018.04.06. eCollection 2018.
To compare the effects of intravitreal anti-vascular endothelial growth factor (VEGF) and dexamethasone in an experimental rabbit model of posterior penetrating ocular injury.
Thirty white New Zealand rabbits were included in the study. A posterior penetrating ocular injury was performed at the superotemporal quadrant. They were randomly divided into three groups. The rabbits in group 1 received intravitreal dexamethasone, in group 2 they received intravitreal bevacizumab and those in group 3 received intravitreal physiological saline solution in both eyes. All eyes were examined ophthalmologically on the 1, 3, 7, 14 and 28 days following the injury and the clinical findings were scored. On the day 28, the eyes were enucleated, evaluated and scored macroscopically, histopathologically and scanning electron microscopically.
The median clinical score on the 14 and 28 days and the median macroscopic score of the dexamethasone group was significantly better than that of control (=0.004, 0.018). Dexamethasone group was also better than that of bevacizumab group but the differences did not reach statistical significance. Retinal detachment rate was 8.3%, 16.6% and 12.5% in the dexamethasone group, bevacizumab group and control group, respectively (=0.476). More extensive fibrocelluler proliferations were observed in controls compared with dexamethasone and bevacizumab groups. But these differences did not reach the statistical significance (=0.538). In scanning electron microscopy all groups showed fibreous stalk and dense collagen fibrils in vitreous.
This study shows that intravitreal injection of both dexamethasone and bevacizumab may reduce the intraocular fibrous proliferation after an experimental posterior penetrating ocular injury in rabbits.
在实验性兔后巩膜穿通伤模型中比较玻璃体内注射抗血管内皮生长因子（VEGF）和地塞米松的效果。
30只白色新西兰兔纳入本研究。在颞上象限造成后巩膜穿通伤。它们被随机分为三组。第1组兔双眼接受玻璃体内注射地塞米松，第2组接受玻璃体内注射贝伐单抗，第3组双眼接受玻璃体内注射生理盐水。在伤后第1、3、7、14和28天对所有眼睛进行眼科检查，并对临床发现进行评分。在第28天，摘除眼球，进行大体、组织病理学和扫描电子显微镜评估及评分。
地塞米松组在第14和28天的临床评分中位数以及大体评分中位数显著优于对照组（P = 0.004，0.018）。地塞米松组也优于贝伐单抗组，但差异未达到统计学意义。地塞米松组、贝伐单抗组和对照组的视网膜脱离率分别为8.3%、16.6%和12.5%（P = 0.476）。与地塞米松组和贝伐单抗组相比，对照组观察到更广泛的纤维细胞增殖。但这些差异未达到统计学意义（P = 0.538）。扫描电子显微镜检查显示，所有组玻璃体内均有纤维状条索和致密的胶原纤维。
本研究表明，玻璃体内注射地塞米松和贝伐单抗均可减少实验性兔后巩膜穿通伤后的眼内纤维增殖。
